A Study of GR1803 in Systemic Lupus Erythematosus
Recruiting
Phase 1
Phase 2
Interventional Study
Systemic Lupus Erthematosus
Auto Immune Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 44 (estimated)
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* comfirmed diagnosis of systemic lupus erythematosus
* SLEDAI-2K≥6分
* written informed consent and ability to comply with protocol requirements
* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Exclusion Criteria:
* with unstable…
Contacts